PMID- 26858332
OWN - NLM
STAT- MEDLINE
DCOM- 20160906
LR  - 20220310
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 34
IP  - 12
DP  - 2016 Apr 20
TI  - Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients 
      With Non-Small-Cell Lung Cancer.
PG  - 1309-14
LID - 10.1200/JCO.2015.65.2560 [doi]
AB  - PURPOSE: Erlotinib depends on stomach pH for its bioavailability. When erlotinib 
      is taken concurrently with a proton pump inhibitor (PPI), stomach pH increases, 
      which results in a clinically relevant decrease of erlotinib bioavailability. We 
      hypothesized that this drug-drug interaction is reversed by taking erlotinib with 
      the acidic beverage cola. The effects of cola on erlotinib bioavailability in 
      patients not treated with a PPI were also studied. PATIENTS AND METHODS: In this 
      randomized, cross-over, pharmacokinetic study in patients with non-small-cell 
      lung cancer, we studied intrapatient differences in absorption (area under the 
      plasma concentration time curve [AUC0-12h]) after a 7-day period of concomitant 
      treatment with erlotinib, with or without esomeprazole, with either cola or 
      water. At the 7th and 14th day, patients were hospitalized for 1 day for 
      pharmacokinetic sampling. RESULTS: Twenty-eight evaluable patients were included 
      in the analysis. In patients treated with erlotinib and esomeprazole with cola, 
      the mean AUC0-12h increased 39% (range, -12% to 136%; P = .004), whereas in 
      patients not treated with the PPI, the mean AUC0-12h was only slightly higher 
      (9%; range, -10% to +30%; P = .03) after erlotinib intake with cola. CONCLUSION: 
      Cola intake led to a clinically relevant and statistically significant increase 
      in the bioavailability of erlotinib during esomeprazole treatment. In patients 
      not treated with the PPI, the effects of cola were marginal. These findings can 
      be used to optimize the management of drug-drug interactions between PPIs and 
      erlotinib.
CI  - (c) 2016 by American Society of Clinical Oncology.
FAU - van Leeuwen, Roelof W F
AU  - van Leeuwen RW
AD  - Roelof W.F. van Leeuwen, Robert Peric, Koen G.A.M. Hussaarts, Emma Kienhuis, 
      Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Bronno van der Holt, 
      Joachim G. Aerts, and Ron H.J. Mathijssen, Erasmus MC Cancer Institute; Roelof 
      W.F. van Leeuwen and Teun van Gelder, Erasmus University Medical Center, 
      Rotterdam; Cor van der Leest and Joachim G. Aerts, Amphia Hospital, Breda; Henk 
      Codrington, Haga Hospital, the Hague; and Jeroen S. Kloover, Elisabeth-Tweesteden 
      Hospital, Tilburg, the Netherlands. r.w.f.vanleeuwen@erasmusmc.nl.
FAU - Peric, Robert
AU  - Peric R
AD  - Roelof W.F. van Leeuwen, Robert Peric, Koen G.A.M. Hussaarts, Emma Kienhuis, 
      Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Bronno van der Holt, 
      Joachim G. Aerts, and Ron H.J. Mathijssen, Erasmus MC Cancer Institute; Roelof 
      W.F. van Leeuwen and Teun van Gelder, Erasmus University Medical Center, 
      Rotterdam; Cor van der Leest and Joachim G. Aerts, Amphia Hospital, Breda; Henk 
      Codrington, Haga Hospital, the Hague; and Jeroen S. Kloover, Elisabeth-Tweesteden 
      Hospital, Tilburg, the Netherlands.
FAU - Hussaarts, Koen G A M
AU  - Hussaarts KG
AD  - Roelof W.F. van Leeuwen, Robert Peric, Koen G.A.M. Hussaarts, Emma Kienhuis, 
      Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Bronno van der Holt, 
      Joachim G. Aerts, and Ron H.J. Mathijssen, Erasmus MC Cancer Institute; Roelof 
      W.F. van Leeuwen and Teun van Gelder, Erasmus University Medical Center, 
      Rotterdam; Cor van der Leest and Joachim G. Aerts, Amphia Hospital, Breda; Henk 
      Codrington, Haga Hospital, the Hague; and Jeroen S. Kloover, Elisabeth-Tweesteden 
      Hospital, Tilburg, the Netherlands.
FAU - Kienhuis, Emma
AU  - Kienhuis E
AD  - Roelof W.F. van Leeuwen, Robert Peric, Koen G.A.M. Hussaarts, Emma Kienhuis, 
      Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Bronno van der Holt, 
      Joachim G. Aerts, and Ron H.J. Mathijssen, Erasmus MC Cancer Institute; Roelof 
      W.F. van Leeuwen and Teun van Gelder, Erasmus University Medical Center, 
      Rotterdam; Cor van der Leest and Joachim G. Aerts, Amphia Hospital, Breda; Henk 
      Codrington, Haga Hospital, the Hague; and Jeroen S. Kloover, Elisabeth-Tweesteden 
      Hospital, Tilburg, the Netherlands.
FAU - IJzerman, Nikki S
AU  - IJzerman NS
AD  - Roelof W.F. van Leeuwen, Robert Peric, Koen G.A.M. Hussaarts, Emma Kienhuis, 
      Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Bronno van der Holt, 
      Joachim G. Aerts, and Ron H.J. Mathijssen, Erasmus MC Cancer Institute; Roelof 
      W.F. van Leeuwen and Teun van Gelder, Erasmus University Medical Center, 
      Rotterdam; Cor van der Leest and Joachim G. Aerts, Amphia Hospital, Breda; Henk 
      Codrington, Haga Hospital, the Hague; and Jeroen S. Kloover, Elisabeth-Tweesteden 
      Hospital, Tilburg, the Netherlands.
FAU - de Bruijn, Peter
AU  - de Bruijn P
AD  - Roelof W.F. van Leeuwen, Robert Peric, Koen G.A.M. Hussaarts, Emma Kienhuis, 
      Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Bronno van der Holt, 
      Joachim G. Aerts, and Ron H.J. Mathijssen, Erasmus MC Cancer Institute; Roelof 
      W.F. van Leeuwen and Teun van Gelder, Erasmus University Medical Center, 
      Rotterdam; Cor van der Leest and Joachim G. Aerts, Amphia Hospital, Breda; Henk 
      Codrington, Haga Hospital, the Hague; and Jeroen S. Kloover, Elisabeth-Tweesteden 
      Hospital, Tilburg, the Netherlands.
FAU - van der Leest, Cor
AU  - van der Leest C
AD  - Roelof W.F. van Leeuwen, Robert Peric, Koen G.A.M. Hussaarts, Emma Kienhuis, 
      Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Bronno van der Holt, 
      Joachim G. Aerts, and Ron H.J. Mathijssen, Erasmus MC Cancer Institute; Roelof 
      W.F. van Leeuwen and Teun van Gelder, Erasmus University Medical Center, 
      Rotterdam; Cor van der Leest and Joachim G. Aerts, Amphia Hospital, Breda; Henk 
      Codrington, Haga Hospital, the Hague; and Jeroen S. Kloover, Elisabeth-Tweesteden 
      Hospital, Tilburg, the Netherlands.
FAU - Codrington, Henk
AU  - Codrington H
AD  - Roelof W.F. van Leeuwen, Robert Peric, Koen G.A.M. Hussaarts, Emma Kienhuis, 
      Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Bronno van der Holt, 
      Joachim G. Aerts, and Ron H.J. Mathijssen, Erasmus MC Cancer Institute; Roelof 
      W.F. van Leeuwen and Teun van Gelder, Erasmus University Medical Center, 
      Rotterdam; Cor van der Leest and Joachim G. Aerts, Amphia Hospital, Breda; Henk 
      Codrington, Haga Hospital, the Hague; and Jeroen S. Kloover, Elisabeth-Tweesteden 
      Hospital, Tilburg, the Netherlands.
FAU - Kloover, Jeroen S
AU  - Kloover JS
AD  - Roelof W.F. van Leeuwen, Robert Peric, Koen G.A.M. Hussaarts, Emma Kienhuis, 
      Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Bronno van der Holt, 
      Joachim G. Aerts, and Ron H.J. Mathijssen, Erasmus MC Cancer Institute; Roelof 
      W.F. van Leeuwen and Teun van Gelder, Erasmus University Medical Center, 
      Rotterdam; Cor van der Leest and Joachim G. Aerts, Amphia Hospital, Breda; Henk 
      Codrington, Haga Hospital, the Hague; and Jeroen S. Kloover, Elisabeth-Tweesteden 
      Hospital, Tilburg, the Netherlands.
FAU - van der Holt, Bronno
AU  - van der Holt B
AD  - Roelof W.F. van Leeuwen, Robert Peric, Koen G.A.M. Hussaarts, Emma Kienhuis, 
      Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Bronno van der Holt, 
      Joachim G. Aerts, and Ron H.J. Mathijssen, Erasmus MC Cancer Institute; Roelof 
      W.F. van Leeuwen and Teun van Gelder, Erasmus University Medical Center, 
      Rotterdam; Cor van der Leest and Joachim G. Aerts, Amphia Hospital, Breda; Henk 
      Codrington, Haga Hospital, the Hague; and Jeroen S. Kloover, Elisabeth-Tweesteden 
      Hospital, Tilburg, the Netherlands.
FAU - Aerts, Joachim G
AU  - Aerts JG
AD  - Roelof W.F. van Leeuwen, Robert Peric, Koen G.A.M. Hussaarts, Emma Kienhuis, 
      Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Bronno van der Holt, 
      Joachim G. Aerts, and Ron H.J. Mathijssen, Erasmus MC Cancer Institute; Roelof 
      W.F. van Leeuwen and Teun van Gelder, Erasmus University Medical Center, 
      Rotterdam; Cor van der Leest and Joachim G. Aerts, Amphia Hospital, Breda; Henk 
      Codrington, Haga Hospital, the Hague; and Jeroen S. Kloover, Elisabeth-Tweesteden 
      Hospital, Tilburg, the Netherlands.
FAU - van Gelder, Teun
AU  - van Gelder T
AD  - Roelof W.F. van Leeuwen, Robert Peric, Koen G.A.M. Hussaarts, Emma Kienhuis, 
      Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Bronno van der Holt, 
      Joachim G. Aerts, and Ron H.J. Mathijssen, Erasmus MC Cancer Institute; Roelof 
      W.F. van Leeuwen and Teun van Gelder, Erasmus University Medical Center, 
      Rotterdam; Cor van der Leest and Joachim G. Aerts, Amphia Hospital, Breda; Henk 
      Codrington, Haga Hospital, the Hague; and Jeroen S. Kloover, Elisabeth-Tweesteden 
      Hospital, Tilburg, the Netherlands.
FAU - Mathijssen, Ron H J
AU  - Mathijssen RH
AD  - Roelof W.F. van Leeuwen, Robert Peric, Koen G.A.M. Hussaarts, Emma Kienhuis, 
      Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Bronno van der Holt, 
      Joachim G. Aerts, and Ron H.J. Mathijssen, Erasmus MC Cancer Institute; Roelof 
      W.F. van Leeuwen and Teun van Gelder, Erasmus University Medical Center, 
      Rotterdam; Cor van der Leest and Joachim G. Aerts, Amphia Hospital, Breda; Henk 
      Codrington, Haga Hospital, the Hague; and Jeroen S. Kloover, Elisabeth-Tweesteden 
      Hospital, Tilburg, the Netherlands.
LA  - eng
SI  - NTR/NTR454
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160208
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - N3PA6559FT (Esomeprazole)
SB  - IM
CIN - J Clin Oncol. 2016 Apr 20;34(12):1295-6. PMID: 26951316
CIN - J Clin Oncol. 2016 Apr 20;34(12):1292-4. PMID: 26976417
EIN - J Clin Oncol. 2016 Aug 10;34(23):2806. PMID: 27488689
CIN - J Clin Oncol. 2016 Nov 20;34(33):4053-4054. PMID: 27551118
CIN - J Clin Oncol. 2016 Nov 20;34(33):4054. PMID: 27551130
CIN - J Clin Oncol. 2016 Nov 20;34(33):4055-4056. PMID: 27551135
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage/blood/*pharmacokinetics
MH  - Area Under Curve
MH  - Biological Availability
MH  - *Carbonated Beverages
MH  - Carcinoma, Non-Small-Cell Lung/blood/*drug therapy/pathology
MH  - Cross-Over Studies
MH  - Drug Monitoring
MH  - Erlotinib Hydrochloride/administration & dosage/blood/*pharmacokinetics
MH  - Esomeprazole/administration & dosage
MH  - Female
MH  - *Food-Drug Interactions
MH  - *Gastrointestinal Absorption
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Lung Neoplasms/blood/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Netherlands
MH  - Protein Kinase Inhibitors/administration & dosage/blood/*pharmacokinetics
MH  - Proton Pump Inhibitors/administration & dosage
EDAT- 2016/02/10 06:00
MHDA- 2016/09/07 06:00
CRDT- 2016/02/10 06:00
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/09/07 06:00 [medline]
AID - JCO.2015.65.2560 [pii]
AID - 10.1200/JCO.2015.65.2560 [doi]
PST - ppublish
SO  - J Clin Oncol. 2016 Apr 20;34(12):1309-14. doi: 10.1200/JCO.2015.65.2560. Epub 
      2016 Feb 8.